Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines

BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic line...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:: 2007

Institución:: Universidad del Rosario

Repositorio:: Repositorio EdocUR - U. Rosario

Idioma:: eng

id	EDOCUR2_74cdbeb641c1c01acdc48eaa2634b058
oai_identifier_str	oai:repository.urosario.edu.co:10336/23840
network_acronym_str	EDOCUR2
network_name_str	Repositorio EdocUR - U. Rosario
repository_id_str
spelling	a2195d85-62be-47cf-b364-516c87b99525-134d7adfc-7134-456f-aeb4-836c0326aec1-1190f891e-b847-4fc0-a11b-9a8fc5bd4399-12020-05-26T00:05:55Z2020-05-26T00:05:55Z2007-11BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic lines with reconstituted and refrigerated toxin (BTX-A) 1 week before its application versus fresh toxin (BTX-A). METHODS: This study was a double-blind, randomized, clinical trial. A total of 30 patients aged 30 to 60 years having a minimum of one and maximum of six external canthus dynamic lines were treated in one canthus with 15 U of BTX-A reconstituted and refrigerated at 4°C 1 week before being applied and in the other with 15 U of fresh BTX-A. Patients were followed-up on Day 10 and Weeks 6, 12, and 18; assessment included a neuroconduction study of the facial nerve and the investigators' photographic evaluation of the number of external canthus dynamic lines at maximum smile. RESULTS: Outcome measurement did not show statistically significant differences between both groups. CONCLUSION: BTX-A, reconstituted and refrigerated 1 week before its application, has similar clinical efficacy in treating external canthus dynamic lines as does fresh BTX-A. © 2007 by the American Society for Dermatologic Surgery, Inc.Introduction: Central pain is one type of pain that occurs in patients with Parkinson's disease (PD). Because of its low incidence and prevalence, it often goes unnoticed and affected patients do not therefore receive adequate analgesic therapy, which increases their suffering. It is a burning pain with spontaneous onset and periods of exacerbation; pain is poorly localised and usually more intense on the more affected side. Its pathophysiology on patients with PD is not clearly defined. Methods: We performed a search and systematic selection of all clinical studies published from January 1986 to September 2010 concerning central neuropathic pain in Parkinson's disease. Conclusions: Treatment with L-Dopa has not been demonstrated to have an analgesic effect on this type of pain. Future studies are required to improve our understanding of this condition, and to develop interventions for preventing and treating it. © 2011 Sociedad Española de Neurología.application/pdfhttps://doi.org/10.1111/j.1524-4725.2007.33284.xhttps://doi.org/10.1097/00042728-200711000-000051076-05121524-4725https://repository.urosario.edu.co/handle/10336/23840eng1333No. 111328Dermatologic SurgeryVol. 33Dermatologic Surgery, ISSN:1076-0512, 1524-4725, Vol.33, No.11 (2007); pp. 1328-1333https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1524-4725.2007.33284.xhttps://journals.lww.com/dermatologicsurgery/Abstract/2007/11000/Clinical_Efficacy_of_Botulinum_Toxin_Type_A.5.aspxBloqueado (Texto referencial)http://purl.org/coar/access_right/c_14cbinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURBotulinum toxin ABotulinum toxin AAdultArticleClinical trialControlled clinical trialControlled studyDouble blind procedureDrug efficacyEyelidFacial nerveFemaleFollow upFreezingHumanMaleNerve conductionPriority journalRandomized controlled trialDilutionDrug potencyDrug stabilityNoteAdultBotulinum Toxin Type ADouble-Blind MethodDrug Administration ScheduleDrug StorageFaceFemaleHumansMaleMiddle AgedNeuromuscular AgentsRefrigerationSkin AgingClinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic linesarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Lizarralde, MónicaGutiérrez, Sara HelenaVenegas, Adriana10336/23840oai:repository.urosario.edu.co:10336/238402022-05-02 07:37:19.450724https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
title	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
spellingShingle	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines Botulinum toxin A Botulinum toxin A Adult Article Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Eyelid Facial nerve Female Follow up Freezing Human Male Nerve conduction Priority journal Randomized controlled trial Dilution Drug potency Drug stability Note Adult Botulinum Toxin Type A Double-Blind Method Drug Administration Schedule Drug Storage Face Female Humans Male Middle Aged Neuromuscular Agents Refrigeration Skin Aging
title_short	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
title_full	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
title_fullStr	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
title_full_unstemmed	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
title_sort	Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
dc.subject.keyword.spa.fl_str_mv	Botulinum toxin A Botulinum toxin A Adult Article Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Eyelid Facial nerve Female Follow up Freezing Human Male Nerve conduction Priority journal Randomized controlled trial Dilution Drug potency Drug stability Note Adult Botulinum Toxin Type A Double-Blind Method Drug Administration Schedule Drug Storage Face Female Humans Male Middle Aged Neuromuscular Agents Refrigeration Skin Aging
topic	Botulinum toxin A Botulinum toxin A Adult Article Clinical trial Controlled clinical trial Controlled study Double blind procedure Drug efficacy Eyelid Facial nerve Female Follow up Freezing Human Male Nerve conduction Priority journal Randomized controlled trial Dilution Drug potency Drug stability Note Adult Botulinum Toxin Type A Double-Blind Method Drug Administration Schedule Drug Storage Face Female Humans Male Middle Aged Neuromuscular Agents Refrigeration Skin Aging
description	BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic lines with reconstituted and refrigerated toxin (BTX-A) 1 week before its application versus fresh toxin (BTX-A). METHODS: This study was a double-blind, randomized, clinical trial. A total of 30 patients aged 30 to 60 years having a minimum of one and maximum of six external canthus dynamic lines were treated in one canthus with 15 U of BTX-A reconstituted and refrigerated at 4°C 1 week before being applied and in the other with 15 U of fresh BTX-A. Patients were followed-up on Day 10 and Weeks 6, 12, and 18; assessment included a neuroconduction study of the facial nerve and the investigators' photographic evaluation of the number of external canthus dynamic lines at maximum smile. RESULTS: Outcome measurement did not show statistically significant differences between both groups. CONCLUSION: BTX-A, reconstituted and refrigerated 1 week before its application, has similar clinical efficacy in treating external canthus dynamic lines as does fresh BTX-A. © 2007 by the American Society for Dermatologic Surgery, Inc.
publishDate	2007
dc.date.created.spa.fl_str_mv	2007-11
dc.date.accessioned.none.fl_str_mv	2020-05-26T00:05:55Z
dc.date.available.none.fl_str_mv	2020-05-26T00:05:55Z
dc.type.eng.fl_str_mv	article
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv	Artículo
dc.identifier.doi.none.fl_str_mv	https://doi.org/10.1111/j.1524-4725.2007.33284.x https://doi.org/10.1097/00042728-200711000-00005
dc.identifier.issn.none.fl_str_mv	1076-0512 1524-4725
dc.identifier.uri.none.fl_str_mv	https://repository.urosario.edu.co/handle/10336/23840
url	https://doi.org/10.1111/j.1524-4725.2007.33284.x https://doi.org/10.1097/00042728-200711000-00005 https://repository.urosario.edu.co/handle/10336/23840
identifier_str_mv	1076-0512 1524-4725
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.citationEndPage.none.fl_str_mv	1333
dc.relation.citationIssue.none.fl_str_mv	No. 11
dc.relation.citationStartPage.none.fl_str_mv	1328
dc.relation.citationTitle.none.fl_str_mv	Dermatologic Surgery
dc.relation.citationVolume.none.fl_str_mv	Vol. 33
dc.relation.ispartof.spa.fl_str_mv	Dermatologic Surgery, ISSN:1076-0512, 1524-4725, Vol.33, No.11 (2007); pp. 1328-1333
dc.relation.uri.spa.fl_str_mv	https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1524-4725.2007.33284.x https://journals.lww.com/dermatologicsurgery/Abstract/2007/11000/Clinical_Efficacy_of_Botulinum_Toxin_Type_A.5.aspx
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_14cb
dc.rights.acceso.spa.fl_str_mv	Bloqueado (Texto referencial)
rights_invalid_str_mv	Bloqueado (Texto referencial) http://purl.org/coar/access_right/c_14cb
dc.format.mimetype.none.fl_str_mv	application/pdf
institution	Universidad del Rosario
dc.source.instname.spa.fl_str_mv	instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv	reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv	Repositorio institucional EdocUR
repository.mail.fl_str_mv	edocur@urosario.edu.co
_version_	1814167619310190592

Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines

Publicaciones similares